You are required to be logged in to access the full website
Click here if you have forgotten your username or password
Therapy Areas: Cardiovascular
US FDA approves new treatments Vyndaqel and Vyndamax for heart disease caused by transthyretin‑mediated amyloidosis
Login
Related Headlines
AstraZeneca invests USD300m to expand US manufacturing for cell therapy
Innovent Biologics announces CFO transition
Cardio Diagnostics appoints Dr Vimal Ramjee as Strategic Advisor
Acticor Biotech reports positive ACTIMIS clinical study results in Lancet Neurology Journal